You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Spinal conditions

Nusinersen for treating spinal muscular atrophy

  • Technology appraisal guidance
  • Reference number: TA588
  • Published:  24 July 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence

  • Evidence review

  • Review outcome summary  (PDF 223 KB)

    Published:
    04 June 2021
  • Company evidence submission (PDF 2.38 MB)

    Published:
    04 June 2021
  • External Assessment Centre (EAC) report (PDF 466 KB)

    Published:
    04 June 2021
  • Company responses to EAC report (PDF 905 KB)

    Published:
    04 June 2021
  • Managed Access Oversight Committee (MAOC) recommendation report (PDF 162 KB)

    Published:
    04 June 2021
  • NICE summary slides (PowerPoint 636 KB)

    Published:
    04 June 2021
  • Outline of objectives  (PDF 209 KB)

    Published:
    04 June 2021
  • Evidence review process (PDF 115 KB)

    Published:
    29 October 2020
  • Nusinersen managed access agreement clinical eligibility criteria evidence review: timeline

  • Evaluation report

  • Final appraisal determination committee papers (PDF 5.4 MB)

    Published:
    24 July 2019
  • Appraisal consultation committee papers (PDF 15.7 MB)

    Published:
    24 July 2019
Back to top